How the Stockholm region will become one of the world’s top five life science centres

Region Stockholm is now stepping up its efforts to become one of the world’s five leading centres for life science by 2025. Martin Tegnér leads the project from his newly setup programme office, which will oversee the initiative to completion.

Martin Tegner.

Tegnér has worked at Karolinska University Hospital since 2016, most recently as a manager of the Region Stockholm Command Center with responsibility for sourcing personal protective equipment during the covid pandemic. The work he did there, together with his colleague Sara Lindholm Larsson, has since been widely praised. He has transferred some of his learnings from that role to his new job.
“It was a very intense period, with a fantastic team, during which we developed the ability to collaborate with everyone moving towards the same goal in a kind of collective movement. Something similar is needed if Region Stockholm is to become one of the world’s five leading life science centres,” says Tegnér.

Key to shared success
The key to success is to get all stakeholders – everyone from researchers to business leaders – to contribute what they’re best at to drive shared success, Tegnér believes.
“Among other things, this requires trust and generosity towards others where no one stands out, and where decisions form collectively without a leader who decides everything.”
The region’s life science strategy sets out the direction and focuses on five development areas, while the programme office’s role will be to ensure the development of concrete action plans.
“This is where the programme office becomes a facilitator and a driving force for success. We become the unifying force and the part of the team that does follow-up,” says Tegnér.
To be successful, we need passionate people who create activities and a critical mass of resources, businesses, operations, and meeting places where people from different professions can meet and identify new forms of collaboration are required.

Flemingsberg well-established
Flemingsberg’s position in Stockholm’s life science cluster is well-established, in part due to the current research and development being done into cell therapies and advanced drug therapies, he says.
“Research has resulted in the formation of a number of businesses that collaborate with researchers and research groups. There are also important infrastructures that complement each other, for example the Pre-GMP lab and Vecura,” says Tengér.
“Flemingsberg Science has taken on the role of enabling innovation and collaboration by connecting a raft of key actors from across the region’s life science cluster.”
Even if Stockholm competes with significantly larger places and regions, size need not be a disadvantage, he believes.
“We can use the fact that we are relatively small as a strength. We offer proximity that makes it easier to get in touch with the right people in the right positions. And that can accelerate our development.”
In addition, Sweden and Stockholm have an extremely strong track record as an innovative country with driven people, especially in life science.
“We’re home to the people behind inventions such as the radiation knife, the dialysis machine and the pacemaker, and many more who have all contributed to our international position. We offer the right conditions and fantastic infrastructure, like SciLifeLab and ANA Futura,” says Tegnér.

Five focus areas for life science success
Region Stockholm’s life science strategy was presented in 2021 and includes five strategic development areas:

  • Access to structured health data and care process data
  • Healthcare and social care available to participate in collaborations with research, innovation and industry
  • Precision medicine gives patients and residents access to high-resolution diagnostics, and personalised prevention and treatment
  • Interdisciplinary collaboration creates solutions to complex challenges
  • Life science companies research, develop and grow in the Stockholm region
Published On: 7 December 2022
  • Now Open: Flemingsberg Science Award STARTUP 2026

    Do you have a business idea that can make a difference, locally or globally? Flemingsberg Science Award STARTUP is the competition for those who want to challenge their idea, gain valuable feedback from experienced experts, and take the first step toward building something real. 

  • Campus Flemingsberg continues to grow – more students and strong collaboration in focus

    Campus Flemingsberg remains one of Sweden’s most dynamic knowledge environments. Over the past year, the number of students has increased from 24,000 to approximately 27,000. The trend is clear: the campus’s broad academic profile continues to attract a growing number of students.

  • Limitless Potential: Winner of the Flemingsberg Science Award 2025

    Young people in disadvantaged areas often face mental health challenges and a lack of support, which can lead to isolation and destructive choices. Limitless Potential, winner of the Flemingsberg Science Award IDEA 2025, has created a safe space where creativity and social entrepreneurship come together to support youth.

  • Alfa Laval strengthens Flemingsberg – establishes itself in a growing city of the future

    In May 2025, Alfa Laval moved into its new office and innovation center, spanning approximately 20,000 square meters, together with around 700 employees. At the same time, the restaurant K-märkt opened, further expanding the range of services available in Flemingsberg. The Royal Swedish Opera and Dramaten, Alfa Laval, Restaurant Billmans, and K-märkt all represent important pieces of the puzzle in the development of Flemingsberg.

  • En nationell resurs för morgondagens behandlingar – nu är Karolinska ATMP Centrum invigt

    Med ett tydligt budskap om framtidstro och ett kraftfullt samarbete invigdes Karolinska ATMP Centrum i Flemingsberg i slutet av augusti. Centret är ett samarbete mellan Karolinska Institutet och Karolinska Universitetssjukhuset, och kommer fungera som en nationell resurs för tillverkning av avancerade terapier (ATMP), där forskning, kliniska prövningar och behandlingar smidigt samverkar för att leverera banbrytande terapier till patienter.